Aurobindo Pharma has been told to schedule a regulatory meeting with the US Food and Drug Administration to discuss current good manufacturing practice compliance problems at three of its bulk drugs facilities.
Giving the Indian producer five days to arrange a meeting over the firm’s Unit XI, I and IX active pharmaceutical ingredient plants, the FDA points out in a warning letter over the Unit XI plant that it had identified similar issues at
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?